Literature DB >> 2603327

Effect of chronic administration of recombinant bovine tumor necrosis factor to cattle.

H Bielefeldt Ohmann1, M Campos, M Snider, N Rapin, T Beskorwayne, Y Popowych, M J Lawman, A Rossi, L A Babiuk.   

Abstract

Cachectin/tumor necrosis factor-alpha (TNF), a protein produced by macrophages upon stimulation, has been implicated as an important mediator of inflammatory processes and of clinical manifestations in chronic infectious diseases. In order to study further the potential role of TNF in infectious diseases, a homologous system was employed in which recombinant Escherichia coli (E. coli) derived bovine TNF (rBoTNF) was injected in cattle, either as a single bolus or in a repetitive treatment-regime. No clinical signs were observed, although changes occurred in hematologic and immunologic parameters when less than 0.5 mg of TNF/100 kg body weight was administered twice daily for 18 days. Prolonged treatment with 0.05-0.5 mg/100 kg induced histologic but no gross changes in the kidneys and liver. When doses were increased above 0.5 mg/100 kg, depression, anorexia, cachexia, and diarrhea appeared rapidly. Pathologic changes were apparent in various tissues including liver, kidneys, and lymphoid organs; body fat depots were depleted. Most of these changes appeared to be reversible; return to normal tissue-morphology occurred within 3 weeks of withdrawal of rBoTNF. The clinical and pathologic changes induced by prolonged rBoTNF administration resembled those observed in some chronic parasitic and viral infections of cattle in which macrophage-activation characteristically occur. Our finding may be relevant to the elucidation of the pathogenesis of these and other chronic infections.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2603327     DOI: 10.1177/030098588902600602

Source DB:  PubMed          Journal:  Vet Pathol        ISSN: 0300-9858            Impact factor:   2.221


  7 in total

1.  Cytokine activity in bovine mammary gland secretions during the periparturient period.

Authors:  L M Sordillo; M J Redmond; M Campos; L Warren; L A Babiuk
Journal:  Can J Vet Res       Date:  1991-07       Impact factor: 1.310

2.  MyD88-dependent recruitment of monocytes and dendritic cells required for protection from pulmonary Burkholderia mallei infection.

Authors:  Andrew Goodyear; Ryan Troyer; Helle Bielefeldt-Ohmann; Steven Dow
Journal:  Infect Immun       Date:  2011-10-24       Impact factor: 3.441

3.  Differential induction of tumor necrosis factor alpha in ovine pulmonary alveolar macrophages following infection with Corynebacterium pseudotuberculosis, Pasteurella haemolytica, or lentiviruses.

Authors:  J A Ellis; M D Lairmore; D T O'Toole; M Campos
Journal:  Infect Immun       Date:  1991-09       Impact factor: 3.441

4.  Lesions and distribution of viral antigen following an experimental infection of young seronegative calves with virulent bovine virus diarrhea virus-type II.

Authors:  J A Ellis; K H West; V S Cortese; S L Myers; S Carman; K M Martin; D M Haines
Journal:  Can J Vet Res       Date:  1998-07       Impact factor: 1.310

5.  Induction of inflammatory cytokines in bovine alveolar macrophages following stimulation with Pasteurella haemolytica lipopolysaccharide.

Authors:  H S Yoo; S K Maheswaran; G Lin; E L Townsend; T R Ames
Journal:  Infect Immun       Date:  1995-02       Impact factor: 3.441

6.  Transcriptional profiling of inflammatory cytokine genes in African buffaloes (Syncerus caffer) infected with Theileria parva.

Authors:  Tomohiro Okagawa; Satoru Konnai; Hirohisa Mekata; Naftaly Githaka; Saori Suzuki; Edward Kariuki; Francis Gakuya; Esther Kanduma; Tatsuya Shirai; Ryoyo Ikebuchi; Yoshinori Ikenaka; Mayumi Ishizuka; Shiro Murata; Kazuhiko Ohashi
Journal:  Vet Immunol Immunopathol       Date:  2012-07-14       Impact factor: 2.046

Review 7.  The pathologies of bovine viral diarrhea virus infection. A window on the pathogenesis.

Authors:  H Bielefeldt-Ohmann
Journal:  Vet Clin North Am Food Anim Pract       Date:  1995-11       Impact factor: 3.357

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.